98%
921
2 minutes
20
Perception of sub-second auditory event timing supports multisensory integration, and speech and music perception and production. Neural populations tuned for the timing (duration and rate) of visual events were recently described in several human extrastriate visual areas. Here we ask whether the brain also contains neural populations tuned for auditory event timing, and whether these are shared with visual timing. Using 7T fMRI, we measured responses to white noise bursts of changing duration and rate. We analyzed these responses using neural response models describing different parametric relationships between event timing and neural response amplitude. This revealed auditory timing-tuned responses in the primary auditory cortex, and auditory association areas of the belt, parabelt and premotor cortex. While these areas also showed tonotopic tuning for auditory pitch, pitch and timing preferences were not consistently correlated. Auditory timing-tuned response functions differed between these areas, though without clear hierarchical integration of responses. The similarity of auditory and visual timing tuned responses, together with the lack of overlap between the areas showing these responses for each modality, suggests modality-specific responses to event timing are computed similarly but from different sensory inputs, and then transformed differently to suit the needs of each modality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroimage.2022.119366 | DOI Listing |
J Pain Palliat Care Pharmacother
September 2025
Spine Unit, Orthopaedic Surgery and Traumatology Department, Catholic University and Polytechnic Hospital, Valencia, Spain.
Dexmedetomidine (DEX) has been proposed as an opioid-sparing adjunct after spinal fusion, but its efficacy across age groups is unclear. We conducted a systematic review and meta-analysis following PRISMA and registered in International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024531252). Twelve studies (RCTs and cohorts; n=1,644) were included.
View Article and Find Full Text PDFInflamm Bowel Dis
September 2025
IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
Background: The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.
Methods: We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).
Plant Commun
September 2025
School of Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK; Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) Gatersleben, Seeland, Germany. Electronic address:
The coordination of floral developmental stages with the environment is important for reproductive success and the optimization of crop yields. The timing of different developmental stages contributes to final yield potential with optimal adaptation enabling development to proceed without being impacted by seasonal weather events, including frosts or end of season drought. Here we characterise the role of FLOWERING LOCUS T 3 (FT3) in hexaploid bread wheat (Triticum aestivum) during the early stages of floral development.
View Article and Find Full Text PDFAnn Vasc Surg
September 2025
Department of Oncology, Anhui Medical University Clinical College of Chest &Anhui Chest Hospital, Hefei, 230022, People's Republic of China.
Objective: This study aimed to characterize the association between pulmonary embolism (PE) onset and various anti-tumor therapeutic approaches in patients with lung cancer, with the goal of identifying potential high-risk populations.
Methods: A retrospective analysis was conducted on clinical records from 2019 to 2025, among the 84,000 inpatients with lung cancer, 106 patients developed PE during hospitalization for anti-tumor treatment, who were confirmed using spiral computed tomography (CT) or pulmonary angiography per CTS (2018) and NEJM (2010) criteria. Data were collected on patient demographics, cancer staging, treatment type, and time to PE onset.